BioInsights - 4D-Nucleofector<sup>®️</sup> LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

4D-Nucleofector®️ LV Unit: Efficient, non-viral large-scale transfection for cell and gene therapy applications

Cell & Gene Therapy Insights 2021; 7(11), 1677

10.18609/cgti.2021.223

Published: 13 December 2021
FastFacts
Timo Gleissner, Andrea Toell

Watch the video or read the poster to learn:

  • An electroporation platform for efficient, non-viral large-scale transfection for cell and gene therapy applications
  • How Nucleofector(R) technology can be applied at scales from 10,000 to 1 billion cells
  • Five key considerations for success in genetic modification for cell therapy

Timo Gleissner is Associate Director Engineering within Bioscience Solutions at Lonza Cologne GmbH and responsible for the technical development of Lonza’s Nucleofector®️ Transfection Platforms. In his current role Timo lead the development of the 4D-Nucleofector®️ LV Unit for large-scale transfection and had the technical responsibility for the product design of the 21CFR part 11 compliant software as well as the TheraPEAK®️ Consumables for GMP manufacturing.

Andrea Toell is a Senior Product Manager at Lonza Cologne GmbH and is responsible for Lonza’s Nucleofector®️ Transfection Portfolio. In her current role she is focusing on large volume transfection and cell and gene therapy applications (CAR-T cells, genome editing, GMP manufacturing). In her 20 years’ experience with the technology she gained a broad knowledge about transfection technologies and factors that are important for successful transfection experiments.